Trial · NCT04362813
Results by group96
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 96
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Participants Who Survived Without Requiring Invasive Mechanical Ventilation From Day 3 to Day 29, Primary Analysis | Canakinumab | 198 | Participants | ||
| Participants Who Survived Without Requiring Invasive Mechanical Ventilation From Day 3 to Day 29, Primary Analysis | Placebo | 191 | Participants | ||
| COVID-19-related Death After Study Treatment | Canakinumab | 11 | Participants | ||
| COVID-19-related Death After Study Treatment | Placebo | 16 | Participants | ||
| Geometric Mean Ratio to Baseline in the C-reactive Protein (CRP) | Canakinumab | Day 2 | 0.726 | 95% Confidence Interval 0.671 to 0.786 | ratio |
| Geometric Mean Ratio to Baseline in the C-reactive Protein (CRP) | Placebo | Day 2 | 0.785 | 95% Confidence Interval 0.722 to 0.853 | ratio |
| Geometric Mean Ratio to Baseline in the C-reactive Protein (CRP) | Canakinumab | Day 3 | 0.479 | 95% Confidence Interval 0.430 to 0.534 | ratio |
| Geometric Mean Ratio to Baseline in the C-reactive Protein (CRP) | Placebo | Day 3 | 0.649 | 95% Confidence Interval 0.578 to 0.729 | ratio |
| Geometric Mean Ratio to Baseline in the C-reactive Protein (CRP) | Canakinumab | Day 5 | 0.255 | 95% Confidence Interval 0.222 to 0.292 | ratio |
| Geometric Mean Ratio to Baseline in the C-reactive Protein (CRP) | Placebo | Day 5 | 0.384 | 95% Confidence Interval 0.325 to 0.454 | ratio |
| Geometric Mean Ratio to Baseline in the C-reactive Protein (CRP) | Canakinumab | Day 7 | 0.160 | 95% Confidence Interval 0.129 to 0.198 | ratio |
| Geometric Mean Ratio to Baseline in the C-reactive Protein (CRP) | Placebo | Day 7 | 0.238 | 95% Confidence Interval 0.195 to 0.290 | ratio |
| Geometric Mean Ratio to Baseline in the C-reactive Protein (CRP) | Canakinumab | Day 9 | 0.131 | 95% Confidence Interval 0.101 to 0.171 | ratio |
| Geometric Mean Ratio to Baseline in the C-reactive Protein (CRP) | Placebo | Day 9 | 0.159 | 95% Confidence Interval 0.126 to 0.201 | ratio |
| Geometric Mean Ratio to Baseline in the C-reactive Protein (CRP) | Canakinumab | Day 11 | 0.099 | 95% Confidence Interval 0.073 to 0.133 | ratio |
| Geometric Mean Ratio to Baseline in the C-reactive Protein (CRP) | Placebo | Day 11 | 0.133 | 95% Confidence Interval 0.096 to 0.185 | ratio |
| Geometric Mean Ratio to Baseline in the C-reactive Protein (CRP) | Canakinumab | Day 13 | 0.108 | 95% Confidence Interval 0.072 to 0.162 | ratio |
| Geometric Mean Ratio to Baseline in the C-reactive Protein (CRP) | Placebo | Day 13 | 0.141 | 95% Confidence Interval 0.087 to 0.228 | ratio |
| Geometric Mean Ratio to Baseline in the C-reactive Protein (CRP) | Canakinumab | Day 15 | 0.133 | 95% Confidence Interval 0.086 to 0.205 | ratio |
| Geometric Mean Ratio to Baseline in the C-reactive Protein (CRP) | Placebo | Day 15 | 0.149 | 95% Confidence Interval 0.088 to 0.252 | ratio |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04362813/results